Blog

Dr. Mark Ball on the future of kidney cancer treatment – NCI Center for Cancer Research

Photo of Mark Ball from NCI Center for Cancer Research/LinkedIn

May 25, 2024, 14:40

Dr. Mark Ball on the future of kidney cancer treatment – NCI Center for Cancer Research

NCI Center for Cancer Research shared on LinkedIn:

“CANCER CURRENTS: In a large clinical trial, treatment with pembrolizumab (Keytruda) after surgery helped people with kidney cancer live longer than those who got a placebo and standard monitoring. The findings mark the first time an adjuvant treatment for kidney cancer has improved survival.

Dr. Mark Ball, an attending surgeon and associate research physician in our Urologic Oncology Branch, weighed in on these findings and what they may mean for the future of kidney cancer treatment.

Read more.”

Stage III Kidney Cancer depiction, courtesy of the NCI.

Source: NCI Center for Cancer Research/LinkedIn

adjuvant treatment for kidney cancer cancer clinical trial improved survival Keytruda kidney cancer Mark Ball NCI Center for Cancer Research OncoDaily Oncology pembrolizumab placebo standard monitoring Urologic Oncology Branch

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage